pyrroles has been researched along with Heart Failure in 142 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.70) | 18.7374 |
| 1990's | 4 (2.82) | 18.2507 |
| 2000's | 64 (45.07) | 29.6817 |
| 2010's | 65 (45.77) | 24.3611 |
| 2020's | 8 (5.63) | 2.80 |
| Authors | Studies |
|---|---|
| Iwahana, T; Kato, H; Kobayashi, Y; Okada, S; Ono, R; Saito, Y | 1 |
| Ben Kridis, W; Charfeddine, S; Khanfir, A; Masmoudi, S | 1 |
| Antonsson, T; Ericsson, C; Hovdal, D; Inghardt, T; Johannesson, P; Johansson, C; Jurva, U; Kajanus, J; Kull, B; Lindstedt, EL; Michaëlsson, E; Pettersen, A; Sjögren, T; Sörensen, H; Westerlund, K | 1 |
| Gregory, J; Hocker, S; Thomason, J | 1 |
| Amilon, C; Ericsson, H; Gan, LM; Han, D; Heijer, M; Kjaer, M; Lagerstrom-Fermer, M; Lindstedt, EL; Michaëlsson, E; Nelander, K; Russell, M; Whatling, C | 1 |
| Ako, J; Fujita, T; Fukaya, H; Ikeda, Y; Ishii, S; Kawaguchi, T; Maemura, K; Minami, Y; Nabeta, T; Naruke, T; Oki, T; Shimohama, T; Yazaki, M; Yuge, M | 1 |
| Banerjee, S; Clark, VR; Fishbein, G; Hong, J; Park, JF; Razee, A; Saddic, L; Umar, S; Williams, T | 1 |
| Aguirre, JI; Aronovitz, MJ; Baca, P; Baumgartner, RA; Blanton, RM; Calamaras, TD; Davis, RJ; Jaffe, IZ; Karas, RH; Kim, SK; Lin, W; Liu, P; Martin, GL; McCarthy, JC; McLaughlin, AL; Pande, S; Richards, DA; Tam, K; Wang, GR | 1 |
| Abernethy, DR; Barnett-Griness, O; Gronich, N; Lavi, I; Rennert, G; Saliba, W | 1 |
| Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Laine, M; Ravaud, A | 1 |
| Cui, W; Hu, HJ; Liu, DM; Liu, J; Wang, Q; Zhang, HL; Zhang, YN | 1 |
| Giaccone, G; Rajan, A; Thomas, A; Tiseo, M | 1 |
| Alani, A; Ghali, JK; Zmily, HD | 1 |
| An, Z; Dong, N; Ge, LL; He, YQ; Li, SM; Yang, G; Zhang, WQ | 1 |
| Dai, XP; Li, XR; Wang, JQ; Wang, Z; Wu, GR | 1 |
| Andalib, S; Garjani, A; Khorrami, A; Maleki-Dijazi, N; Shayanfar, A | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
| Stewart, R; White, J | 1 |
| Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX | 1 |
| Chen, W; Gao, DC; Ye, PX; Ye, PZ; Zhu, JH | 1 |
| Hopper, I; Krum, H | 1 |
| Choi, D; Hong, N; Kang, SM; Lee, SH; Oh, J; Park, S; Youn, JC | 1 |
| Akiyama, E; Kimura, K; Kosuge, M | 1 |
| Athanasiou, D; Chrysohoou, C; Hatzis, G; Mazaris, S; Mourouzis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tourikis, P; Tousoulis, D; Zaromitidou, M; Zisimos, K | 1 |
| El Messaoudi, S; Noyez, L; Rongen, GA; Thijs, AM; van der Graaf, WT; van Herpen, CM; van Swieten, H; Verweij, V; Vos, JC; Wouterse, AC | 1 |
| Chen, Y; Hou, X; Qian, Z; Wang, Y; Yuan, J; Zhang, X; Zou, J | 1 |
| Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J | 1 |
| Frazier, OH; Hamilton, DJ; Li, Y; Rees, ML; Subramaniam, J; Taegtmeyer, H | 1 |
| Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L | 1 |
| Ha, AS; Imran, TF; Joseph, J; Shah, R; Thomas, R | 1 |
| Beuselinck, B; Punie, K; Schöffski, P; Van Cleemput, J; Van Keerberghen, CA; Van Limbergen, E; Van Wambeke, S; Wildiers, H; Wolter, P | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kwok, K; Riese, R; Soma, K; Wicker, P; Zuckerman, A | 1 |
| Deedwania, P; Singh, V | 1 |
| Ford, JS; Tayek, JA | 1 |
| Martin, J | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT | 1 |
| Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC | 1 |
| Kumar, SK; Mather, PJ | 1 |
| Goldsmith, SR | 1 |
| Assmann, G; Breithardt, G; Nofer, JR; Schubert, A; Schulte, H; Stypmann, J; Welp, H | 1 |
| von Haehling, S | 1 |
| Cui, W; Liu, F; Lu, JC; Pei, WN; Xie, RQ; Yang, C | 1 |
| Kotyla, PJ | 1 |
| Nurzyński, P; Opolski, G; Szaluś, N; Szczylik, C; Szmit, S | 1 |
| Chen, Y; Cheng, X; Ding, Y; Liao, M; Liao, YH; Tang, T; Wang, M; Xia, C; Xie, J; Yao, R; Yu, X | 1 |
| Jarkowski, A; Wong, MK | 1 |
| Kurzyna, M; Opolski, G; Szczylik, C; Szmit, S; Zagrodzka, M | 1 |
| Campese, VM; Ku, E; Nobakht, N | 1 |
| Chen, MH | 1 |
| Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Strandberg, TE; Tikkanen, MJ | 1 |
| Kishi, T; Okamatsu, S; Sunagawa, K; Yamada, A | 1 |
| Chuang, WP; Hsiao, CH; Li, AH; Wu, CF | 1 |
| Anker, SD; Földes, G; von Haehling, S | 1 |
| Haass, M | 1 |
| Fukuda, H; Izoe, Y; Kohno, H; Nomoto, T; Oshita, A; Sueda, S | 1 |
| Breazna, A; Deedwania, PC; DeMicco, DA; Greten, H; LaRosa, JC; Shepherd, J; Wenger, NK | 1 |
| Haseke, N; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Reilly, T; Schork, MR | 1 |
| Ghali, JK; Tam, SW | 1 |
| Strandberg, TE | 1 |
| Chapman, RH; Roberts, CS; Yeaw, J | 1 |
| Funder, JW | 1 |
| Ducharme, A; Dupuis, J; Jiang, BH; Martin, JG; Sauvageau, S; Shi, Y; Tardif, JC | 1 |
| Chang, SG; Jeon, SH; Lee, CH; Lee, JH; Lim, TJ; Min, GE; Yoo, KH | 1 |
| Singh, M; Slawsky, MT; Valania, G | 1 |
| Daifallah, S; Farah, JO; Ghali, JK; Zmily, HD | 1 |
| Cantillo, DS; Comín Colet, J; Robledo, GG | 1 |
| Villabona, C | 1 |
| Alcaino, H; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; López, R; Mellado, R; Navarro, M; Nogerol, C; Tapia, F; Verdejo, HE | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Er, F; Fuhr, U; Gassanov, N; Nia, AM; Semmo, M; Semmo, N | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Nazer, B; Ray, KK; Scirica, B; Sloan, S | 1 |
| Daifallah, S; Ghali, JK; Khan, NS; Zmily, HD | 1 |
| Andalib, S; Biabani, S; Doustar, Y; Garjani, A; Maleki-Dizaji, N; Soraya, H | 1 |
| Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Ozova, EM | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Choueiri, TK; Dallabrida, SM; Heng, DY; Je, Y; Moslehi, JJ; Richards, CJ; Schutz, FA | 1 |
| Greineder, CF; Kohnstamm, S; Ky, B | 1 |
| Gupta, R; Maitland, ML | 1 |
| Korkor, MT; Liu, B; Liu, JY; Song, XJ; Wei, Q; Yang, CY; Yang, P | 1 |
| Correll, RN; Hajjar, RJ; Houser, SR; Ishikawa, K; Kawase, Y; Ladage, D; Molkentin, JD; Tilemann, L | 1 |
| Fonarow, GC; Horwich, TB; Maclellan, WR; Middlekauff, HR | 1 |
| Braunwald, E; Cannon, CP; Grandin, EW; Jarolim, P; Morrow, DA; Murphy, SA; Ritterova, L | 1 |
| Takagi, H; Umemoto, T | 1 |
| Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Mizuno, K; Shinada, T; Shirakabe, A; Tomita, K; Tsurumi, M; Yokoyama, S | 1 |
| Breazna, A; Deedwania, PC; Demicco, DA; Ho, JE; Kean, A; Khush, KK; Waters, DD; Wilson, DJ; Wun, CC | 1 |
| Abraham, WT; Ghali, JK; Orlandi, C | 1 |
| Geisberg, C; Pentassuglia, L; Sawyer, DB | 1 |
| Dabrowska, MD; Krysiak, R; Okopień, B | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Doevendans, PA; Goumans, MJ; Pasterkamp, G; Post, S; Rensing, BJ; van den Broek, AJ | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| Borne, RT; Krantz, MJ | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
| Rose, S | 1 |
| Blei, AT; Blendis, LM; Thuluvath, PJ; Wong, F | 1 |
| Ferguson, JW; Hayes, PC; Newby, DE; Therapondos, G | 1 |
| Böhm, M; Fries, R | 1 |
| Thibonnier, M | 1 |
| Bahlmann, FH; Drexler, H; Engberding, N; Fuchs, M; Haller, H; Heineke, A; Hilfiker-Kleiner, D; Hornig, B; Kotlarz, D; Landmesser, U; Mueller, M; Schaefer, A; Spiekermann, S; Templin, C; Wiencke, A | 1 |
| Antoniades, C; Bosinakou, E; Kotsopoulou, M; Pitsavos, C; Stefanadis, C; Tentolouris, C; Tousoulis, D; Trikas, A; Tsioufis, C | 1 |
| Antoniades, C; Bosinakou, E; Kotsopoulou, M; Panagiotakos, D; Pitsavos, C; Stefanadis, C; Tousoulis, D; Vlachopoulos, C | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Molyneux, SL; Scott, RS; Strey, CH; Young, JM | 1 |
| Antoniades, C; Pitsavos, C; Stefanadis, C; Tentolouris, C; Tousoulis, D; Toutouza, M; Trikas, A; Vassiliadou, C | 1 |
| Gheorghiade, M; Orlandi, C; Zimmer, CA | 1 |
| van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Hamaad, A; Lip, GY; MacFadyen, RJ; Sosin, M | 1 |
| Lawler, RL; Letterer, RA; Levy, WC; McDonald, GB; Minami, E; Mozaffarian, D | 1 |
| Esberg, D; Kowey, P | 1 |
| Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Starc, V; Vrtovec, B | 1 |
| Khan, BV; Lerakis, S; Mir, MQ; Sola, S; Tandon, N | 1 |
| Badziński, A; Dyrbuś, K; Mercik, G; Nowak, J; Nowalany-Kozielska, E; Poloński, L; Rozek, MM; Szyguła-Jurkiewicz, B; Wilczek, K; Wodniecki, J; Wojnicz, R; Zembala, M | 1 |
| Greenberg, A; Verbalis, JG | 1 |
| Frampton, CM; Lainchbury, JH; Nicholls, MG; Richards, AM; Scott, RS; Strey, CH; Young, JM | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Loh, PH; Tin, L | 1 |
| Gong, K; Song, G; Zhang, Z | 1 |
| Omland, T; Solberg, OG | 1 |
| Bittner, V; Deedwania, PC; Kastelein, JJ; Khush, KK; Lewis, SJ; Waters, DD; Wenger, NK | 1 |
| Bao, XF; Cai, HW; Cheng, G; Wang, HH; Xu, G | 1 |
| Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P | 1 |
| Fukunami, M; Kioka, H; Masuda, M; Mine, T; Morita, T; Node, K; Okuda, K; Tamaki, S; Tsukamoto, Y; Yamada, T | 1 |
| Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
| Abdellah, AT; Clark, AL; Cleland, JG; Coletta, AP; Khaleva, O | 1 |
| Horwich, TB; MacLellan, WR | 1 |
| Cassiola, F; Chen, JH; Chen, MH; Chu, TF; Dallabrida, SM; Demetri, GD; Desai, J; Force, T; George, S; Harris, DM; Ismail, NS; Kerkela, R; Morgan, JA; Nguyen, L; Pravda, E; Rupnick, MA; Schoen, FJ; Van den Abbeele, AD; Woulfe, K; Zurakowski, D | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Hobbs, RE; Tang, WH | 1 |
| Bletard, N; Bonbled, F; Duck, L; Jacquet, L; Machiels, JP; Pirenne, P | 1 |
| Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Schlegel, TT; Starc, V; Vrtovec, B | 1 |
| Asakura, M; Asanuma, H; Kato, H; Kim, J; Kitakaze, M; Liao, Y; Minamino, T; Ogai, A; Takashima, S; Zhao, H | 1 |
| Alcaino, H; Bustos, C; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; Mellado, R; Miranda, R; Verdejo, HE; Vukasovic, JL | 1 |
| Bickford, C; Champion, JC; Durand, JB; Halushka, M; Kassiotis, CM; Khakoo, AY; Lenihan, DJ; Plana, JC; Tannir, N; Trent, J | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Scott, RS; Sies, CW; Strey, CH; Young, JM | 1 |
| Fisher, GA; Srinivas, S; Telli, ML; Witteles, RM | 1 |
| Schweiger, TA; Zdanowicz, MM | 1 |
| Satoh, K | 1 |
| Handrock, R; Haverich, A; Herzig, S; Hirt, S; Mittmann, C; Schröder, F | 1 |
| Albright, JD; Bailey, T; Cervoni, P; Chan, PS; Coupet, J; Dusza, JP; Hartupee, D; Lai, F; Lock, TY; Mazandarani, H; Ning, X; Ochalski, L; Park, HC; Ru, X; Shepherd, C; Spinelli, W; Tanikella, T; Taylor, JR | 1 |
| Abraham, WT; Lieming, X; Martin, PY; Ohara, M; Olson, BR; Oren, RM; Schrier, RW | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Gerckens, U; Grube, E; Irmisch, R; Lahn, T; Mengden, T; Metzger, H; Sigel, H; Wagner, WL | 1 |
46 review(s) available for pyrroles and Heart Failure
| Article | Year |
|---|---|
Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment.
Topics: Animals; Benzamides; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation; Electrolytes; Heart Failure; Humans; Hyponatremia; Outpatients; Pyrroles; Receptors, Vasopressin; Sodium; Treatment Outcome | 2013 |
Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies.
Topics: Atorvastatin; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MEDLINE; Prospective Studies; Pyrroles | 2014 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
Statins and congestive heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2008 |
Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Hyponatremia; Infusions, Intravenous; Male; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Risk Assessment; Survival Rate; Tolvaptan; Water-Electrolyte Imbalance | 2008 |
Pharmacology of vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Benzodiazepines; Heart Failure; Humans; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2009 |
AVP receptor antagonists in patients with CHF.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Sodium | 2009 |
Treatment options for hyponatremia in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Pyrroles; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2009 |
Statins for heart failure: still caught in no man's land?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Evidence-Based Medicine; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Pyrroles | 2009 |
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Lixivaptan: a novel vasopressin receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Kidney Diseases; Pyrroles; Receptors, Vasopressin | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab | 2009 |
[Vasopressin receptor antagonists and heart failure].
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Female; Follow-Up Studies; Furosemide; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Indoles; Male; Morpholines; Platelet Aggregation Inhibitors; Pyrroles; Pyrrolidines; Sodium Potassium Chloride Symporter Inhibitors; Spiro Compounds; Time Factors; Tolvaptan | 2009 |
Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
Topics: Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Neurotransmitter Agents; Pyrroles; Tolvaptan; Vasopressins | 2010 |
The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Blood Pressure; Blood Volume; Female; Heart Failure; Humans; Hypertension; Hyponatremia; Male; Prevalence; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; United States; Water-Electrolyte Balance | 2010 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone | 2010 |
Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?
Topics: Acute Disease; Animals; Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Hyponatremia; Prognosis; Pyrroles; Tolvaptan; Vasoconstriction; Vasopressins | 2011 |
Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Clinical Trials as Topic; Dogs; Heart Failure; Humans; Hyponatremia; Pyrroles; Rats | 2010 |
[Hyponatremia in heart failure: physiopathology and pharmacological approach].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Brain Edema; Demyelinating Diseases; Diuresis; Diuretics; Double-Blind Method; Heart Failure; Humans; Hyponatremia; Kidney; Multicenter Studies as Topic; Natriuresis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Saline Solution, Hypertonic; Sympathetic Nervous System; Tolvaptan | 2010 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Biological; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan; Water-Electrolyte Balance | 2011 |
The potential role for lixivaptan in heart failure and in hyponatremia.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Heart Failure; Humans; Hyponatremia; Plasma Volume; Pyrroles | 2011 |
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Follow-Up Studies; Heart Failure; Humans; Incidence; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Heart failure associated with sunitinib: lessons learned from animal models.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiotoxins; Disease Models, Animal; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Kidney Neoplasms; Mitochondria; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Signal Transduction; Sunitinib | 2011 |
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Heart Failure; Humans; Hypertension; Indoles; Myocytes, Cardiac; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Risk Factors; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2011 |
Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials.
Topics: Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke Volume; Sulfonamides | 2012 |
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2012 |
[Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Hyponatremia; Hypovolemia; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan | 2012 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Diuretics; Heart Failure; Homeostasis; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Animal; Morpholines; Piperidines; Pyrroles; Quinolones; Rats; Spiro Compounds; Vasopressins | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2003 |
Role of vasopressin antagonists in the management of acute decompensated heart failure.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Stroke Volume; Tolvaptan; Treatment Outcome; Vasoconstriction; Vasopressins | 2005 |
Vasopressin receptor antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins | 2006 |
[Arginine vasopressin antagonism--new treatment option in chronic heart failure].
Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Nephrons; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; Vasoconstrictor Agents | 2007 |
Therapeutic potential of vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2007 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
Atorvastatin and statins in the treatment of heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Agents; Drug Interactions; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Pyrroles; Treatment Outcome | 2007 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2006 |
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
[Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
Topics: Animals; Benzopyrans; Calcium Channel Blockers; Cromakalim; Guanidines; Heart Failure; Hemodynamics; Humans; In Vitro Techniques; Ion Channel Gating; Niacinamide; Nicorandil; Pinacidil; Potassium Channels; Pyrroles; Vasodilator Agents | 1993 |
VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Blood Pressure; Cyclic AMP; Dogs; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney; Pyrroles; Receptors, Vasopressin | 1998 |
36 trial(s) available for pyrroles and Heart Failure
| Article | Year |
|---|---|
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Healthy Volunteers; Heart Failure; Humans; Male; Middle Aged; Peroxidase; Pyrimidines; Pyrroles; Single-Blind Method; Stroke Volume; Ventricular Function, Left; Young Adult | 2021 |
[Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension].
Topics: Aged; Atorvastatin; C-Reactive Protein; Double-Blind Method; Endothelins; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles | 2014 |
Effect of high-dose statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure. Randomized, controlled, open-label, prospective pilot study.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Female; Heart Failure; Heptanoic Acids; Hospital Mortality; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Prospective Studies; Pyrroles | 2014 |
Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Atorvastatin; Biomarkers; Brachial Artery; Cell Movement; Cross-Over Studies; Double-Blind Method; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Glycoproteins; Greece; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Myocardial Ischemia; Peptides; Pyrroles; Recovery of Function; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor Receptor-2; Vasodilation | 2015 |
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left | 2015 |
Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure.
Topics: Atorvastatin; Echocardiography; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Protein Precursors; Pyrroles; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2008 |
Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Electrocardiography; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long QT Syndrome; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2010 |
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Topics: Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2009 |
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Coronary Restenosis; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Heart Diseases; Heart Failure; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters.
Topics: Allopurinol; Atorvastatin; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Pyrroles; Regional Blood Flow; Treatment Outcome; Xanthine Oxidase | 2011 |
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Neopterin; Pravastatin; Proportional Hazards Models; Pyrroles; Sensitivity and Specificity; Treatment Outcome | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvastatin; Blood Pressure; C-Reactive Protein; Carbazoles; Carvedilol; Chronic Disease; Drug Therapy, Combination; Elasticity; Female; Heart Failure; Heptanoic Acids; Humans; Interleukin-6; Male; Metoprolol; Middle Aged; Myocardial Ischemia; Propanolamines; Pyrroles; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Resistance | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peroneal Nerve; Pyrroles; Stroke Volume; Surveys and Questionnaires; Sympathetic Nervous System; Time Factors; Ventricular Function, Left | 2011 |
Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Matrix Metalloproteinase 2; Prognosis; Pyrroles; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
Topics: Adult; Aged; Atorvastatin; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies | 2012 |
The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzamides; Body Weight; Double-Blind Method; Female; Health Status Indicators; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Outpatients; Pyrroles; Statistics as Topic; Stroke Volume; Ventricular Function, Left; Young Adult | 2012 |
Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Glomerular Filtration Rate; Greece; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Incidence; Male; Prognosis; Pyrroles; Reference Values; Survival Rate; Treatment Outcome | 2012 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Ascites; Azepines; Benzamides; Edema; Female; Heart Failure; Hemodynamics; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Male; Middle Aged; Norepinephrine; Pyrroles; Renin; Sodium; Thirst; Treatment Outcome; Water-Electrolyte Balance | 2003 |
Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Endothelium, Vascular; Fibrinolysis; Forearm; Heart Failure; Heptanoic Acids; Humans; Hyperemia; Lipids; Middle Aged; Pyrroles; Regional Blood Flow; Vasodilation | 2005 |
Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cytokines; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Forearm; Heart Failure; Heptanoic Acids; Humans; Hyperemia; Inflammation; Male; Middle Aged; Pyrroles; Regional Blood Flow; Vascular Cell Adhesion Molecule-1 | 2005 |
Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Coenzymes; Cross-Over Studies; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ubiquinone; Vascular Resistance; Vasodilation | 2005 |
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure.
Topics: Aged; Antioxidants; Atorvastatin; Biomarkers; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vasodilation; Vitamin E | 2005 |
Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure.
Topics: Adult; Aged; Atorvastatin; Autonomic Nervous System; Female; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Single-Blind Method; Systole | 2005 |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
Topics: Adult; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Receptors, Tumor Necrosis Factor, Type I; Treatment Outcome | 2005 |
Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atorvastatin; Electrocardiography; Female; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prospective Studies; Pyrroles; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2005 |
Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.
Topics: Atorvastatin; C-Reactive Protein; Double-Blind Method; Erythrocytes; Female; Heart Failure; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Pilot Projects; Pyrroles; Receptors, Tumor Necrosis Factor, Type II; Stroke Volume; Superoxide Dismutase; Systole; Ultrasonography; Ventricular Function, Left | 2006 |
Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels.
Topics: Adult; Atorvastatin; Cardiomyopathy, Dilated; Cholesterol, LDL; Drug Therapy, Combination; Endpoint Determination; Evaluation Studies as Topic; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Myocardium; Pyrroles; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2006 |
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure.
Topics: Atorvastatin; Biomarkers; Cholesterol; Cross-Over Studies; Double-Blind Method; Echocardiography; Endothelium, Vascular; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptides; Pyrroles; Vascular Resistance; Vasodilation | 2006 |
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Drug Delivery Systems; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Pyrroles | 2007 |
Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
Topics: Aged; Atorvastatin; Atrial Natriuretic Factor; Disease-Free Survival; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Stroke Volume; Ventricular Dysfunction, Left | 2007 |
Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.
Topics: Atorvastatin; Death, Sudden, Cardiac; Disease Progression; Female; Health Status Indicators; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Risk Factors; Stroke Volume | 2008 |
Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure.
Topics: Arginine; Atorvastatin; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ventricular Dysfunction, Left | 2008 |
Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure.
Topics: Administration, Oral; Aged; Aquaporin 2; Aquaporin 6; Aquaporins; Arginine Vasopressin; Azepines; Benzamides; Biomarkers; Blotting, Western; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Pyrroles; Reference Values; Sensitivity and Specificity | 1999 |
60 other study(ies) available for pyrroles and Heart Failure
| Article | Year |
|---|---|
Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
Topics: Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Patient Safety; Pyrroles; Retrospective Studies; Stroke Volume; Sulfones; Treatment Outcome | 2021 |
Sunitinib-Induced Congestive Heart Failure in a Patient with Gastrointestinal Stromal Tumor.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Pyrroles; Sunitinib | 2022 |
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
Topics: Animals; Heart Failure; Humans; Iodide Peroxidase; Peroxidase; Pyrimidines; Pyrroles; Stroke Volume | 2022 |
Toceranib phosphate resolves right heart obstruction secondary to a heart base neoplasm in a dog.
Topics: Animals; Dog Diseases; Dogs; Heart Block; Heart Failure; Heart Neoplasms; Male; Pyrroles | 2022 |
Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure.
Topics: Heart Failure; Humans; Hypertension; Pyrroles; Sulfones; Treatment Outcome | 2021 |
Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Heart Failure; Heart Ventricles; Humans; Hypoxia; Indoles; Male; Middle Aged; Monocrotaline; Pulmonary Arterial Hypertension; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; RNA-Seq; Transcriptome; Ventricular Dysfunction, Right; Ventricular Remodeling | 2021 |
MLK3 mediates impact of PKG1α on cardiac function and controls blood pressure through separate mechanisms.
Topics: Animals; Aorta; Blood Pressure; Cyclic GMP-Dependent Protein Kinase Type I; Heart Failure; HEK293 Cells; Humans; Hypertension; Male; MAP Kinase Kinase Kinases; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase Kinase Kinase 11; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrroles; Sildenafil Citrate; Vascular Stiffness; Vasodilator Agents; Ventricular Dysfunction, Left | 2021 |
Tyrosine kinase-targeting drugs-associated heart failure.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Case-Control Studies; Cetuximab; Cohort Studies; Heart Failure; Humans; Incidence; Indoles; Israel; Middle Aged; Neoplasms; Odds Ratio; Panitumumab; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sunitinib; Trastuzumab | 2017 |
Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.
Topics: Aged; Carcinoma, Renal Cell; Heart Failure; Humans; Hypertension, Pulmonary; Indoles; Liver Neoplasms; Male; Pyrroles; Sunitinib | 2017 |
Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway.
Topics: Aldosterone; Animals; Atorvastatin; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Chronic Disease; DNA; Fibroblasts; Flow Cytometry; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2013 |
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Heart Failure; Humans; Indoles; Male; Middle Aged; Prognosis; Pyrroles; Sunitinib; Thymus Neoplasms | 2013 |
Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio.
Topics: Animals; Atorvastatin; Collagen; Disease Models, Animal; Female; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-2; Ventricular Remodeling | 2013 |
Atorvastatin reduces the myocardial content of coenzyme Q10 in isoproterenol-induced heart failure in rats.
Topics: Animals; Antioxidants; Atorvastatin; Heart Failure; Heptanoic Acids; Isoproterenol; Lipid Peroxidation; Lipids; Male; Malondialdehyde; Myocardium; Pyrroles; Rats; Rats, Wistar; Ubiquinone | 2014 |
Bias in the evaluation of effects of statins on mortality in patients with heart failure.
Topics: Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2014 |
Statins in CHF.
Topics: Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2014 |
Is high-dose statin loading effective for acute decompensated heart failure? Insight of inflammation and acute kidney injury.
Topics: Acute Kidney Injury; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyrroles | 2014 |
Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle.
Topics: Adult; Aged; Coronary Artery Bypass; Electric Stimulation; Female; Heart Atria; Heart Failure; Humans; Indoles; Ischemia; Male; Middle Aged; Myocardial Contraction; Myocardium; Pyrroles; Reperfusion Injury; Solvents; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Amrinone; Animals; Arrhythmias, Cardiac; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Electric Stimulation; Electrocardiography; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gs; Guinea Pigs; Heart Failure; In Vitro Techniques; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Pyrroles; Receptors, Adrenergic, beta-2; Thionucleotides; Ventricular Function | 2015 |
A PKM2 signature in the failing heart.
Topics: Angiogenesis Inhibitors; Animals; Carrier Proteins; Fetal Heart; Gene Expression; Glucose; Glycolysis; Heart; Heart Failure; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin Resistance; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Pyrroles; Pyruvate Kinase; Sunitinib; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2015 |
Heart failure associated with small molecule tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2016 |
A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation Therapy.
Topics: Female; Heart Failure; Humans; Hypokinesia; Indoles; Middle Aged; Pyrroles; Sunitinib; Triple Negative Breast Neoplasms | 2017 |
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Topics: Arthritis, Rheumatoid; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Hyperlipidemias; Hypertension; Incidence; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2016 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Atorvastatin pleiotropic effects mediated via suppression of TNF-alpha in congestive heart failure patients with initial normal TNF-alpha levels.
Topics: Animals; Apoptosis; Atorvastatin; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Pyrroles; Reference Values; Tumor Necrosis Factor-alpha | 2009 |
Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Blood Pressure; Carcinoma, Renal Cell; Diuretics; Drug Therapy, Combination; Electrocardiography; Female; Furosemide; Gated Blood-Pool Imaging; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Metoprolol; Pyrroles; Sunitinib; Treatment Outcome; Troponin | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Biomarkers; Case-Control Studies; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-18; Interleukin-4; Male; Middle Aged; Pyrroles; Th1 Cells; Th2 Cells | 2009 |
Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Echocardiography; Heart Failure; Heart Neoplasms; Humans; Indoles; Male; Middle Aged; Poland; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Glomerular Filtration Rate; Heart Failure; Heart Ventricles; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrroles; Retrospective Studies; Ventricular Premature Complexes | 2009 |
Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement.
Topics: Aged; Antineoplastic Agents; Electrocardiography; Female; Gadolinium; Heart Failure; Humans; Image Enhancement; Indoles; Magnetic Resonance Imaging; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Heart Failure; Heptanoic Acids; Humans; Pyrroles; Signal Transduction; Th1 Cells; Th2 Cells | 2009 |
Vasospastic heart failure: multiple spasm may cause transient heart failure?
Topics: Acute-Phase Reaction; Adrenergic beta-Antagonists; Aged; Asian People; Calcium Channel Blockers; Coronary Vasospasm; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Stroke Volume; Ventricular Function, Left | 2009 |
Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.
Topics: Aged; Carcinoma, Renal Cell; Echocardiography; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Natriuretic Peptide, Brain; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thrombosis | 2010 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Patient Compliance; Pyrroles; Retrospective Studies; United States | 2010 |
Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure.
Topics: Animals; Atorvastatin; Cells, Cultured; Heart Failure; Heptanoic Acids; Lung; Myocardial Infarction; Myofibroblasts; Pyrroles; Random Allocation; Rats; Respiratory Function Tests | 2010 |
Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate.
Topics: Acute Kidney Injury; Angioplasty, Balloon, Coronary; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Agents; Coronary Stenosis; Fatal Outcome; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multiple Organ Failure; Protein Kinase Inhibitors; Pyrroles; Renal Dialysis; Sunitinib; Treatment Outcome | 2010 |
Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.
Topics: Animals; Atorvastatin; Body Weight; Drug Interactions; Heart Failure; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Male; Myocardium; Organ Size; Pyrroles; Rats; Rats, Wistar; Ubiquinone; Ventricular Dysfunction, Left | 2011 |
Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 12; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Heart Failure; Heat-Shock Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Myocardial Infarction; Natriuretic Peptide, Brain; Pyrroles; Rats; Rats, Wistar; Transcription Factor CHOP | 2011 |
Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury.
Topics: Animals; Cardiac Output; Coronary Occlusion; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Heart; Heart Failure; Indoles; Maleimides; Myocardial Contraction; Myocardial Infarction; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Pyrroles; Stroke Volume; Swine | 2011 |
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Female; Galectin 3; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from the REPERATOR study.
Topics: Adult; Aged; Atorvastatin; Cell Movement; Chemokine CXCL12; Dipeptidyl Peptidase 4; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardium; Pyrroles | 2012 |
Lixivaptan for hyponatremia--the numbers game.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Biomarkers; Data Interpretation, Statistical; Drug Approval; Heart Failure; Humans; Hyponatremia; Length of Stay; Pyrroles; Risk; Severity of Illness Index; Sodium; Treatment Outcome; United States; United States Food and Drug Administration | 2012 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2013 |
Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.
Topics: Animals; Atorvastatin; Biological Availability; Capillaries; Cells, Cultured; Collateral Circulation; Drug Resistance; Endothelial Cells; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Random Allocation; Ultrasonography; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2004 |
Statins and autonomic function in chronic heart failure.
Topics: Atorvastatin; Autonomic Nervous System; Chronic Disease; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Does "anti-lipid" also mean "anti-arrhythmic"?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atorvastatin; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902.
Topics: Anemia; Atorvastatin; Cardiology; Clinical Trials as Topic; Congresses as Topic; Darbepoetin alfa; Diuretics; Erythropoietin; Europe; Exercise Tolerance; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Societies, Medical; Xanthines | 2006 |
Statin therapy for patients with chronic heart failure.
Topics: Atorvastatin; Cholesterol; Diastole; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2006 |
Effect of atorvastatin on non-ischemic heart failure and matrix metalloproteinase-2 and 9 in rats.
Topics: Animals; Arteriovenous Fistula; Atorvastatin; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ultrasonography | 2007 |
Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.
Topics: Acute Disease; Amides; Atorvastatin; Cardiac Pacing, Artificial; Clinical Trials as Topic; Fumarates; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pulmonary Edema; Pyrroles; Renin; Respiration, Artificial | 2007 |
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Female; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Male; Mice; Middle Aged; Multicenter Studies as Topic; Protein-Tyrosine Kinases; Pyrroles; Rats; Retrospective Studies; Stroke Volume; Sunitinib | 2007 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Acute cardiac failure after sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2008 |
Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
Topics: Animals; Atorvastatin; Cardiomegaly; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Heart Failure; Heparin-binding EGF-like Growth Factor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Phosphorylation; Pyrroles; Ventricular Function, Left | 2008 |
Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
Topics: Aged; Atorvastatin; Biomarkers; Brachial Artery; Chronic Disease; Endothelium, Vascular; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Time Factors; Vasodilation; Walking | 2008 |
Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib | 2008 |
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Probability; Protein-Tyrosine Kinases; Pyrroles; Registries; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Stroke Volume; Sunitinib; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Single-channel properties of L-type calcium channels from failing human ventricle.
Topics: Adult; Aged; Calcium; Calcium Channel Agonists; Calcium Channels; Female; Heart; Heart Failure; Heart Ventricles; Humans; Ion Channel Gating; Male; Middle Aged; Patch-Clamp Techniques; Pyrroles | 1998 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bridged Bicyclo Compounds; Bridged-Ring Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Pyrroles; Ramipril | 1989 |